News | July 27, 2012

Accuray Rolls Out Comprehensive Customer Service Program in Japan

Company strengthens commitment to Japanese market, supporting growth of TomoTherapy system globally

July 27, 2012 — Accuray Inc. announced the extension of its Emerald Service Program for the TomoTherapy system, which provides equipment protection and product updates that improve clinical uptime and enhance technology utilization, to customers throughout Japan. As part of its ongoing commitment to strengthening customer service globally, Accuray will now interact directly with TomoTherapy customers in Japan to provide service programs in the Japanese radiation oncology market.

"We are dedicated to helping advance radiation oncology treatment in Japan, and this is a significant move toward ensuring that our current and future customers throughout the country benefit from the highest quality customer service," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "We have seen clear traction for both the TomoTherapy and CyberKnife systems in Japan and believe that by managing the service program directly, we will be able to increase touch points with our customers, hear about their needs firsthand and reaffirm their confidence in our products."

The TomoTherapy system received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) in December 2004, and the first TomoTherapy system was installed in 2005. Presently there are 26 TomoTherapy systems and 25 CyberKnife robotic radiosurgery systems in use in Japan.

Previously, Hitachi Medical Corp. provided service and support for TomoTherapy customers in Japan. With the rollout of the Emerald Service Program, Hitachi Medical will transfer the regulatory approval and service business to Accuray. The move to take service in-house provides new opportunities for growth and further market penetration for both the CyberKnife and TomoTherapy systems in Japan. Accuray forecasts that the transfer of the service business from Hitachi Medical to Accuray will drive an increase in service revenue.

Accuray and Hitachi Medical will continue to partner on sales and distribution, enabling Accuray to benefit from Hitachi Medical's deep territory penetration in the Japan's radiation oncology market. Accuray expects the relationship to also provide opportunities for future growth of the TomoTherapy business globally.

For more information: www.accuray.com

Related Content

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" will be presented by Par
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
Overlay Init